1. Home
  2. HAE

as of 11-16-2026 3:41pm EST

$121.39
$1.63
-1.32%
Stocks Health Care Medical/Dental Instruments Nasdaq

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.

Founded: 1971 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 5.4B IPO Year: 1996
Target Price: $147.18 AVG Volume (30 days): 591.2K
Analyst Decision: Buy Number of Analysts: 12
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 1.72 EPS Growth: -38.07
52 Week Low/High: $51.00 - $132.00 Next Earning Date: 11-05-2026
Revenue: $910,373,000 Revenue Growth: -3.00%
Revenue Growth (this year): 8.17% Revenue Growth (next year): 10.82%
P/E Ratio: 71.52 Index:
Free Cash Flow: 260.4M FCF Growth: +16.46%

AI-Powered HAE Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

sell
Model Precision: 100.00%
100.00%
AI Precision

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Haemonetics Corporation (HAE)

Maunsell Farris Maryanne

VP, Chief Accounting Officer

Sell
HAE Nov 11, 2026

Avg Cost/Share

$120.99

Shares

836

Total Value

$101,147.64

Owned After

5,828

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 5, 2026 · 100% conf.

AI Prediction SELL

1D

-1.93%

$124.96

Act: -3.39%

5D

-4.78%

$121.32

20D

+1.13%

$128.87

Price: $127.42 Prob +5D: 0% AUC: 1.000
0000313143-26-000150

EX-99.1

2 ex991-fy27q2earningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Investor ContactsMedia Contact

Olga Guyette, Vice President-Investor Relations & TreasuryJosh Gitelson, Sr. Director-Global Communications

(781) 356-9763(781) 356-9776

olga.guyette@haemonetics.com josh.gitelson@haemonetics.com

David Trenk, Sr. Manager-Investor Relations

(203) 733-4987

david.trenk@haemonetics.com

Haemonetics Reports Second Quarter and First Half Fiscal 2027 Results;

Updates Fiscal 2027 Guidance

Boston, MA, November 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its second quarter of fiscal 2027, which ended September 26, 2026:

2nd Quarter 2027

Year-to-Date 2027

nRevenue, increase $358 million, 9%

$697 million, 8%

n Organic(1) revenue increase 10.0%8.0%

nEarnings per diluted share$1.00$1.72

nAdjusted earnings per diluted share$1.35$2.49

nCash flow from operating activities$128 million$180 million

nFree cash flow$104 million$143 million


(1)    Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.

Chris Simon, Haemonetics’ CEO, stated: “Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”

GAAP RESULTS

Second quarter fiscal 2027 revenue was $357.8 million, up 9.3% compared with the second quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:

Second Quarter Fiscal 2027 Reported

(Dollars in Millions)

Apheresis$204.812.6%

MedSurg$153.05.1%

Total net revenue$357.89.3%

1

Gross margin was 61.7% in the second quarter of fiscal 2027, compared with 59.5% in the second quarter of fiscal 2026. The primary drivers of the increase in the gross margin percentage included tariffs refunded, the continued transformation of the product portfolio to higher-margin offerings and the absence of amortization of fair value inventory step-up. Operating expenses were $145.8 million, up $9.5 million, or 7.0%, compared with the second quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $75.1 million and a 21.0% operating margin in the second quarter of fiscal 2027, compared with operating income of $58.5 million and a 17.9% operating margin in the second quarter of fiscal 2026. The effective income tax rate was 26.3% in the second quarter of fiscal 2027, compared with 24.6% in the second quarter of fiscal 2026. The increase in the effective income tax rate was primarily due to valuation allowances recorded against deferred tax assets in jurisdictions with losses from recent acquisitions. Second quarter fiscal 2027 net income and earnings per diluted share were $46.3 million and $1.00, respectively, compared with $38.7 million and $0.81, respectively, in the second quarter of fiscal 2026.

ADJUSTED RESULTS

Second quarter organic revenue growth was 10.0% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:

Second Quarter Fiscal 2027

Organic

Apheresis13.6%

MedSurg5.5%

Total net revenue10.0%

Second quarter fiscal 2027 adjusted gross margin was 61.9%, up 140 basis points compared with the prior year period. The primary drivers of the increase in the adjusted gross margin percentage included tariffs refunded and the continued transformation of the product portfolio to higher-margin offerings, partially offset by foreign currency fluctuations.

Adjusted operating expenses were $127.6 million, up $16.8 million, or 15.2%, compared with the second quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the second quarter of fiscal 2027 was $94.1 million, up $6.8 million, or 7.8%, compared with the second quarter of fiscal 2026. Adjusted operating margin was 26.3%, down 40 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the second quarter of fiscal 2027 was 24.7%, which was flat when compared with 24.7% in the second quarter of fiscal 2026.

Second quarter fiscal 2027 adjusted net income was $62.6 million, up $2.3 million, or 3.8%, and adjusted earnings per diluted share was $1.35, up 6.3%, each when compared with the same period of fiscal 2026.

BALANCE SHEET AND CASH FLOW

Cash on hand as of September 26, 2026 was $260.7 million, an increase of $15.3 million since the end of fiscal 2026, primarily driven by cash flow provided from operating activities, partially offset by cash outflows

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 6, 2026 · 100% conf.

AI Prediction BUY

1D

+1.86%

$86.60

Act: +3.32%

5D

+4.47%

$88.82

20D

+6.32%

$90.39

Price: $85.02 Prob +5D: 100% AUC: 1.000
0000313143-26-000118

EX-99.1

2 ex991-fy27q1earningsrelease.htm

EX-99.1

Document

Exhibit 99.1

Investor ContactsMedia Contact

Olga Guyette, Vice President-Investor Relations & TreasuryJosh Gitelson, Sr. Director-Global Communications

(781) 356-9763(781) 356-9776

olga.guyette@haemonetics.com josh.gitelson@haemonetics.com

David Trenk, Sr. Manager-Investor Relations

(203) 733-4987

david.trenk@haemonetics.com

Haemonetics Reports First Quarter Fiscal 2027 Results;

Raises Total Company Fiscal 2027 Guidance

Boston, MA, August 6, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first quarter of fiscal 2027, which ended June 27, 2026:

1st Quarter 2027

nRevenue, increase $339 million, 5.6%

n Organic(1) revenue increase 5.9%

nEarnings per diluted share$0.72

nAdjusted earnings per diluted share$1.14

nCash flow from operating activities$52 million

nFree cash flow$39 million


(1)    Excludes the impacts of currency fluctuation and the exit of certain liquid solution products.

Chris Simon, Haemonetics’ CEO, stated: “We had a strong start to fiscal 2027, gaining Plasma share, sustaining Blood Management Technologies momentum, and returning Interventional Technologies to growth. With our evolved portfolio, transformed operating model and disciplined execution, we are strengthening our competitive position and demonstrating the durable growth of our diversified businesses. We raised full-year guidance, and Haemonetics is well-positioned to deliver sustainable long-term growth and shareholder value.”

1

GAAP RESULTS

First quarter fiscal 2027 revenue was $339.4 million, up 5.6% compared with the first quarter of fiscal 2026. Business unit revenue and growth rates compared with the prior year period were as follows:

First Quarter Fiscal 2027 Reported

(Dollars in Millions)

Apheresis$191.35.3%

MedSurg$148.16.0%

Total net revenue$339.45.6%

Gross margin was 59.8% in the first quarter of fiscal 2027, which was relatively flat when compared with 59.8% in the first quarter of fiscal 2026. Operating expenses were $145.3 million, up $7.0 million, or 5.0%, compared with the first quarter of fiscal 2026. The increase in operating expenses was driven by higher personnel-related costs and freight charges. The Company had operating income of $57.5 million and a 16.9% operating margin in the first quarter of fiscal 2027, compared with operating income of $53.9 million and a 16.8% operating margin in the first quarter of fiscal 2026. The effective income tax rate was 30.6% in the first quarter of fiscal 2027, compared with 24.7% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls and valuation allowance impacts related to losses in certain recently acquired jurisdictions. First quarter fiscal 2027 net income and earnings per diluted share were $33.0 million and $0.72, respectively, compared with $34.0 million and $0.70, respectively, in the first quarter of fiscal 2026.

ADJUSTED RESULTS

First quarter organic revenue growth was 5.9% compared with the same period of fiscal 2026. Year-over-year organic revenue growth rates by business unit were as follows:

First Quarter Fiscal 2027

Organic

Apheresis6.0%

MedSurg5.9%

Total net revenue5.9%

First quarter fiscal 2027 adjusted gross margin was 60.4%, down 40 basis points compared with the prior year period. The primary drivers of the decrease in the adjusted gross margin percentage included upfront revenue recognition upon the execution of a long-term software agreement in the prior year, partially offset by the continued transformation of the product portfolio to higher-margin offerings and benefits from product innovation.

Adjusted operating expenses were $125.6 million, up $7.9 million, or 6.7%, compared with the first quarter of fiscal 2026. The increase in adjusted operating expenses was driven by higher personnel-related costs and freight charges. Adjusted operating income for the first quarter of fiscal 2027 was $79.3 million, down $1.7 million, or 2.2%, compared with the first quarter of fiscal 2026. Adjusted operating margin was 23.4%, down 70 basis points when compared with the same period of fiscal 2026. The adjusted income tax rate for the first quarter of fiscal 2027 was 25.7%, up 180 basis points when compared with 24.9% in the first quarter of fiscal 2026. The increase in the effective income tax rate was primarily driven by stock compensation shortfalls.

First quarter fiscal 2027 adjusted net income was $52.3 million, up $0.9 million, or 1.8%, and adjusted earnings per diluted share was $1.14, up 3.6%, each when compared with the same period of fiscal 2026.

2

BALANCE SHEET AND CASH FLOW

Cash on hand as of June 27, 2026 was $223.4 million, a decrease of $22.1 million since the end of fiscal 2026, primarily driven by cash outflows for the repayment of revolving credit facility borrowings and strategic investments, partially offset by cash flow pro

2026
Q1

Q1 2026 Earnings

8-K BUY

May 7, 2026 · 100% conf.

AI Prediction BUY

1D

+1.98%

$55.45

Act: +1.12%

5D

+4.37%

$56.75

Act: +5.06%

20D

+2.20%

$55.56

Act: +31.10%

Price: $54.37 Prob +5D: 100% AUC: 1.000
0000313143-26-000031

EX-99.1

2 ex991-q4mar2026earningsrel.htm

EX-99.1

Document

Exhibit 99.1

Investor ContactsMedia Contact

Olga Guyette, Vice President-Investor Relations & TreasuryJosh Gitelson, Sr. Director- Global Communications

(781) 356-9763(781) 356-9776

olga.guyette@haemonetics.comjosh.gitelson@haemonetics.com

David Trenk, Manager-Investor Relations

(203) 733-4987

david.trenk@haemonetics.com

Haemonetics Reports Fourth Quarter and Fiscal 2026 Results;

Provides Fiscal 2027 Guidance

Boston, MA, May 7, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial results for its fourth quarter and fiscal 2026, which ended March 28, 2026:

Fourth Quarter Fiscal 2026Fiscal 2026

n Revenue, increase/(decrease)

$346 million, 4.8%

$1.334 billion, (2.0)%

n Organic(1) revenue increase 4.5%1.1%

n Organic ex-CSL(2) revenue increase 8.6%9.5%

n (Loss) earnings per diluted share $(0.44)$2.05

n Adjusted earnings per diluted share $1.29$4.96

n Cash flow from operating activities $71 million$293 million

n Free cash flow $45 million$210 million


(1)    Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. The Company's acquisition of Vivasure Medical Limited ("Vivasure") in January 2026 had no impact on organic revenue growth rates and is not separately quantified.

(2)    In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Chris Simon, Haemonetics’ CEO, stated: "Strong fourth quarter performance was largely driven by our core platforms, with outperformance in Plasma and Blood Management Technologies, and sequential improvement in Interventional Technologies. We successfully completed our four-year long-range plan, having built a more diversified, sustainable, and durable business and delivering impressive results against ambitious multi-year goals. With a strengthened competitive position and focus on disciplined execution, we have momentum for fiscal 2027 and beyond."

GAAP RESULTS

Fourth quarter fiscal 2026 revenue was $346.4 million, up 4.8% compared with the fourth quarter of fiscal 2025. Business unit revenue and growth rates compared with the prior year period were as follows:

Fourth Quarter Fiscal 2026 Reported

(Dollars in Millions)

Plasma$130.32.8%

Blood Center$56.40.7%

Hospital$159.68.0%

Total net revenue$346.44.8%

1

Gross margin was 57.2% in the fourth quarter of fiscal 2026, compared with 58.4% in the fourth quarter of fiscal 2025. The primary driver of the decrease in the gross margin percentage was a charge taken for pre-acquisition inventory and inventory purchase commitments transferred from the Attune Medical acquisition that was deemed not recoverable, partially offset by decreased restructuring costs related to portfolio rationalization initiatives and decreased amortization of fair value inventory step-up.

Operating expenses in the fourth quarter of fiscal 2026 were $221.2 million, an increase of $99.5 million, or 81.8%, when compared with the prior year period, driven by the impairment of intangible assets related to Attune Medical, partially offset by remeasurements of contingent consideration. Due to these charges, the Company had operating losses of $23.0 million and a (6.6)% operating margin in the fourth quarter of fiscal 2026, compared with operating income of $71.3 million and an operating margin of 21.6% in the fourth quarter of fiscal 2025. The income tax rates were 29.1% and 18.0% in the fourth quarters of fiscal 2026 and fiscal 2025, respectively. Additionally, due to the charges above, fourth quarter fiscal 2026 net loss and loss per diluted share were $20.1 million and $(0.44), respectively, compared with net income and earnings per diluted share of $58.0 million and $1.17, respectively, in the fourth quarter of fiscal 2025.

ADJUSTED RESULTS

Fourth quarter fiscal 2026 organic revenue growth was 4.5% and organic ex-CSL revenue growth was 8.6% compared with the same period of fiscal 2025. Year-over-year organic and organic ex-CSL growth rates by business unit were as follows:

Fourth Quarter Fiscal 2026

OrganicOrganic ex-CSL

Plasma1.8%12.7%

Blood Center5.5%5.5%

Hospital6.5%6.5%

Total net revenue4.5%8.6%

Fourth quarter fiscal 2026 adjusted gross margin was 59.7%, down 50 basis points compared with the prior year period. The primary drivers for the decrease in adjusted gross margin percentage were less favorable mix and impacts from tariffs, partially offset by higher volume and pricing benefits.

Adjusted operating expenses were $122.2 million, up $5.5 million, or 4.7%, when compared with the prior year period. The increase in adjusted operating expenses was largely driven by the acquisition of Vivasure, impacts from tariff and performance-based compensation as well as additional growth investments. A

Share on Social Networks: